BioPharma Dive July 31, 2024
The company is developing a medicine for alpha-1 antitrypsin deficiency, competing with companies like Sanofi and Wave Life Sciences.
Dive Brief:
- RNA editing startup Airna is adding more funds to its Series A round, raising another $60 million as it develops genetic medicines for lung, cardiovascular, metabolic and blood diseases.
- The Boston- and Germany-based biotechnology company made its debut last September with $30 million, launching with a plan to develop a medicine for the rare inherited disorder alpha-1 antitrypsin deficiency.
- Proceeds from the round will help the company take its AATD drug candidate into the clinic as early as next year, said Kris Elverum, Airna’s CEO.
Dive Insight:
Airna describes its drugmaking approach as a safer alternative to...
Today's Sponsors
Today's Sponsor